Telotristat ethyl (Xermelo)


Indications for Prior Authorization:

  • Treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy

Patients must meet the following criteria for the indication(s) above:

  • Diagnosis of carcinoid syndrome diarrhea

  • 18 years of age or older
  • Patient is followed by a specialist (oncologist or gastroenterologist)
  • Patient is inadequately controlled on maximum SSA therapy and needs additional therapy
  • Approval for a maximum of 250mg three times daily


  • 250mg orally three times daily with food

  • If used in combination with short-acting octretotide, administer octreotide at least 30 minutes after telotristat ethyl


  • Initial: 3 months

  • Renewal: 1 year

Last review date: May 1, 2017

The site you are transferring to is not hosted by WHA. WHA's Terms of Use and internet Privacy Practices do not apply to your use of this linked site. Please review the policies on privacy and terms of use for the linked site. WHA does not control the accuracy, completeness, or timeliness of the content on the linked site.

Press Esc to cancel

El sitio Web al que está siendo transferido no es provisto por WHA. Las Condiciones de Uso y las Prácticas de Privacidad en Internet de WHA no se aplican a este sitio Web asociado que usted está usando. Revise las políticas sobre la privacidad y condiciones de uso de este sitio Web asociado. WHA no tiene control sobre la exactitud, la totalidad o la actualidad del contenido del sitio Web asociado. WHA no puede garantizar que los servicios de traducción de idiomas estarán disponibles en el sitio vinculado.

Presione «Esc» para cancelar